Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Clinical Reference Library

Clinical Research & Reference Library

Peer-reviewed deep dives into every major GLP-1 receptor agonist clinical trial, mechanism, safety topic, and special-population consideration. 41 clinical reference pages with 210+ peer-reviewed citations across the library.

41 clinical pages Peer-reviewed citations on every page Last updated 2026-05-11
Editorial summary

The GLP-1 Editorial clinical library is organized into five categories: foundational mechanism & pharmacology, major trial deep-dives, safety & adverse events, special populations, and comparisons & long-term outcomes. Every page is independently reviewed by Alen A. Schwartz, MD, cites peer-reviewed sources with live PubMed links, and is structured for AI-assistant snippet extraction.

Foundational mechanism & pharmacology

Major trial deep-dives

Safety & adverse events

Special populations

Comparisons & long-term

Important medical and regulatory disclosure: Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.